Business Wire

Percona Augments Corporate Governance with the Appointment of Two New Independent Directors

Share

Percona, a global leader in enterprise-grade open source database software and services, today announced the addition of two preeminent technology business leaders – John Newton, Co-Founder of Alfresco and Documentum, and Rob Young, a veteran of the open source software ecosystem – as independent directors to its board. The appointments expand the wealth of business strategy, industry expertise and strategic counsel the Percona board offers CEO Ann Schlemmer and her leadership team.

John Newton brings over 40 years of experience in the enterprise software industry, having played a pivotal role in the development and success of numerous companies. A serial entrepreneur, John co-founded Documentum, which was acquired by EMC in 2003, and Alfresco, an open source platform for information management, which had a successful exit with its sale to Hyland Software in 2020. John began his career as one of the founding engineers at Ingres Corporation, where he led the development of their database management system. His innovative contributions to data and information management have earned him several prestigious awards, including recognition as a Technology Pioneer at the World Economic Forum in Davos in 2006 and the Award of Merit from the Association for Intelligent Information Management (AIIM) in 2023. John holds a BS in Electrical Engineering and Computer Science from the University of California, Berkeley, and has served on the boards of several leading companies, including Alfresco, Wideworks, and AIIM.

Rob Young is a seasoned business and technology executive with four decades of experience in building and delivering enterprise solutions through an open source development and delivery model. During his career, Rob has held key technical and leadership positions across various industries, including finance, transportation, healthcare, public utilities, and commercial software and services. Rob has been a driving force in establishing open source software as a trusted foundation for digital transformation. He was instrumental in developing growth strategies and business models focused on value-added differentiation and customer satisfaction in numerous strategic roles at MySQL AB, MongoDB, Percona, RedHat, and DigitalOcean. Notably, while with MySQL AB, Rob led the design, development, and delivery of MySQL Enterprise, which quadrupled the company's revenue in just two years and culminated in a $1 billion acquisition by Sun Microsystems. Rob holds a Bachelor of Science in Economics and Math from the University of Louisville and resides in Louisville, KY.

“We are honored to welcome John Newton and Rob Young to our board,” said Ann Schlemmer, CEO of Percona. “Their extensive experience and deep understanding of the industry will be invaluable as we continue to innovate and deliver world-class solutions to our customers. Their leadership and vision will be crucial as we navigate the opportunities and challenges ahead, ensuring we maintain the highest standards of corporate governance.”

These appointments come at a pivotal time for Percona as the company reaffirms its commitment to cloud-native development with the introduction of Percona Everest and expands its footprint into the Redis ecosystem through its involvement with the Linux Foundation’s Valkey Project. With the addition of John Newton and Rob Young, Percona is well-positioned to accelerate growth and continue its mission of empowering enterprises with robust, reliable, and scalable open source database solutions.

About Percona

Percona is a world-class open source database software, support, and services company. The organization is dedicated to helping businesses ensure their databases — and the applications that depend on them — are secure, compliant, performant, and highly available. Through a unique combination of database expertise and enterprise-grade open source software, Percona empowers organizations with the freedom to choose, the freedom to create, and the freedom to innovate with speed as they grow. For more information, visit www.percona.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240815431864/en/

Contacts

Jacob Manchester
Scratch Marketing + Media for Percona
jacob@scratchmm.com
401-636-7757

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kweichow Moutai’s Brand Culture Activities in Greece Foster Sino-Greek Cultural Cooperation21.12.2024 19:41:00 CET | Press Release

On December 9th, the exhibition “Longevity in the Tao of Chrysanthemum: The Artistic World of Qi Baishi,” supported by Kweichow Moutai Group, opened at the Athens University History Museum. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241221429801/en/ Gao Shan(R3), and Petros Tatoulis(R2), took a group photo with other guests at the opening ceremony of the exhibition. (Photo: Business Wire) Featuring the works of Qi Baishi, a renowned Chinese painter, the exhibition highlights the unique charm of traditional Chinese culture for Western audiences, while advancing cultural exchange and mutual understanding between China and Greece. Gao Shan, Chairman of the Labor Union at Kweichow Moutai Distillery (Group) Co., Ltd., remarked on the significance of the event, saying, “Qi Baishi employed distinctive Eastern painting techniques to convey the Chinese perspective of the world. Athens, a city celebrated for its great masters and

Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai

HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release

Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa

SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release

On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye